August 18, 2017

On August 17, Representatives Elijah Cummings (D-MD) and Peter Welch (D-VT), members of the US House of Representatives Committee on Oversight and Government Reform, announced the start of an in-depth investigation into the dramatic increases in costs for multiple sclerosis (MS) drugs.  The Committee cited a 2015  study published in Neurology®. This development shows that the work the AAN has undertaken to address drug costs in the US is clearly working. In February 2017, the AAN approved a new  Position Statement on Prescription Drug Prices in addition to its 2015  Position Statement on Disease-Modifying Therapies in MS, and we followed this up by taking this issue to Congress as part of our 15th  Neurology on the Hill, where over 215 AAN members told their own stories about the impact of drug costs on their patients. We have continued to raise this issue through our interactions with members of Congress and their staff and are pleased these efforts have been noticed. The issue of unsustainable drug costs affects everyone, but particularly neurology patients.  


Have Questions?
Let Member Services Help!
Have Feedback? Let Us Know